Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1572359

This article is part of the Research TopicAdvancement of Chemotherapy in Breast Cancer: Predictive Markers, Resistance Mechanism and Therapeutic StrategiesView all 10 articles

Elevated KNSTRN as a potential indicator for triple-negative breast cancer progression and immune infiltration

Provisionally accepted
Yuan  CaoYuan Cao1*Yurong  SongYurong Song1Yuxi  LiuYuxi Liu2Minfang  QiMinfang Qi2
  • 1960th Hospital of the PLA, Jinan, China
  • 2Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Region, China

The final, formatted version of the article will be published soon.

Background: Kinetochore localized astrin/SPAG5 binding protein (KNSTRN) is a protein-coding gene pivotal for the mitotic spindle's operation, ensuring accurate chromosome separation and transition into anaphase. Existing literature indicates that it is associated with a variety of cancers. However, there is a lack of research to confirm that it is related to the malignant phenotype and immune infiltration of triple-negative breast cancer (TNBC). The objective of this study was to ascertain the potential role of KNSTRN in TNBC prognosis, immune infiltration and progression. Methods: We analyzed KNSTRN expression in TNBC using RNA-seq and single-cell transcriptome data from TCGA, GEO, and METABRIC datasets, correlating it with clinical features, prognosis, and immune infiltration. Functional enrichment analyses identified pathways regulated by KNSTRN in TNBC. In vitro siRNA knockdown in TNBC cell lines (MDA-MB-231 and BT549) assessed its impact on proliferation, migration, and DNA synthesis. RNA-seq was performed on BT549 cells with KNSTRN knockdown to validate the findings from the bioinformatic analysis. Immunohistochemistry was used to validate KNSTRN expression in tissue of patients with TNBC and other subtypes of breast cancer (Non-TNBC), as well as the association of KNSTRN expression and CD8+ T cell infiltration in TNBC. Results: KNSTRN was significantly overexpressed in TNBC compared to those in other breast cancer subtypes and normal tissues. High expression of KNSTRN is associated with a poor prognosis in TNBC. Functional enrichment analysis revealed that KNSTRN-associated differentially expressed genes (DEGs) were involved in cell cycle regulation, metabolism, and immune response pathways. Immune infiltration analysis showed that high KNSTRN expression was associated with reduced infiltration of CD8+ T cells. In vitro experiments confirmed that KNSTRN knockdown inhibited This is a provisional file, not the final typeset article TNBC cell proliferation and migration. RNA-seq on BT549 cells with KNSTRN knockdown also validated that KNSTRN played a role in promoting cell cycle progression and cell proliferation. Conclusions: KNSTRN is a candidate biomarker for TNBC prognosis and a potential target for immunotherapeutic strategies. Its overexpression in TNBC is associated with aggressive tumor behavior and an immunosuppressive microenvironment, highlighting its significance in TNBC pathogenesis and prognosis.

Keywords: KNSTRN, TNBC, prognosis, Immune infiltration, tumor progression

Received: 07 Feb 2025; Accepted: 07 Oct 2025.

Copyright: © 2025 Cao, Song, Liu and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yuan Cao, labs.net@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.